阿扎胞苷、维奈克拉与吉瑞替尼三联方案治疗新诊断FLT3突变AML的长期结局
中位随访41.5个月,完全缓解/完全缓解伴血液学恢复不全率为96%,中位无复发生存期和总生存期分别为23.4个月和29.7个月,3年无复发生存率和总生存率分别为43%和46%。
要点
- 三联方案在不适合强化化疗的FLT3突变AML中诱导缓解率高,达96%。
- 中位随访41.5个月,中位无复发生存期23.4个月,总生存期29.7个月。
- 基线RAS通路突变与更差结局相关。
核心结论
- 阿扎胞苷、维奈克拉与吉瑞替尼三联方案与持久缓解及令人鼓舞的长期生存相关。
- 需要随机研究将该方案与标准治疗进行比较。
研究设计与样本
- 中位年龄71岁,22例(73%)携带FLT3内部串联重复(FLT3-ITD)突变。
- 试验注册号NCT04140487。
主要发现
- 完全缓解/完全缓解伴血液学恢复不全率为96%,14例(47%)在首次缓解期接受异基因造血干细胞移植。
- 中位随访41.5个月,11例(37%)复发;在可评估的复发中,67%检测不到FLT3突变。
- 中位无复发生存期和总生存期分别为23.4个月和29.7个月,3年无复发生存率和总生存率分别为43%和46%。
- 在FLT3-ITD突变患者中,中位无复发生存期和总生存期分别为17.0个月和21.8个月,3年无复发生存率和总生存率分别为32%和36%。
- 基线RAS通路突变与更差结局相关;首次缓解期是否接受造血干细胞移植对生存率无显著影响。
关键数值与推荐
- 在接受≥1个巩固疗程的患者中,68%至少一种研究药物的剂量或疗程减少。
临床怎么用
- 对于不适合强化化疗的新诊断FLT3突变AML患者,可考虑阿扎胞苷、维奈克拉与吉瑞替尼三联低强度方案。
- 治疗中需注意剂量或疗程调整,68%接受巩固治疗的患者至少一种药物减量或缩短疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among patients with FLT3-mutated acute myeloid leukemia (AML) who receive frontline azacitidine plus venetoclax, relapses are commonly driven by the expansion of the FLT3-mutated clone, supporting FLT3 inhibitor-based triplet lower-intensity regimens. We report long-term outcomes of a phase 2 study of azacitidine, venetoclax, and gilteritinib for adults with newly diagnosed FLT3-mutated AML who were unfit for intensive chemotherapy. Thirty patients were treated; median age was 71 years, and 22 (73%) had an FLT3 internal tandem duplication (FLT3-ITD) mutation. The complete remission (CR)/CR with incomplete hematologic recovery rate was 96%, and 14 patients (47%) underwent allogeneic hematopoietic stem cell transplantation (HSCT) in first remission. With a median follow-up of 41.5 months, 11 patients (37%) relapsed; in 67% of evaluable relapses, the FLT3 mutation was not detectable. The median relapse-free survival (RFS) and overall survival (OS) were 23.4 and 29.7 months, respectively, and the 3-year RFS and OS rates were 43% and 46%, respectively. Among patients with FLT3-ITD-mutated AML, the median RFS and OS were 17.0 and 21.8 months, respectively, and the 3-year RFS and OS rates were 32% and 36%, respectively. The presence of a baseline RAS pathway mutation was associated with worse outcomes. Survival rates were similar regardless of HSCT in first remission. Among patients who received ≥1 consolidation cycle, 68% had a reduction in the dose or duration of at least one of the study drugs. The triplet regimen of azacitidine, venetoclax, and gilteritinib is associated with durable remissions and encouraging long-term survival. Randomized studies comparing this regimen to standard of care approaches are warranted. This trial was registered at www.clinicaltrials.gov as #NCT04140487.
引用
- Short NJ, Kantarjian H, Daver N, et al. Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML. Blood Adv. 2026. PMID: 42200455. doi:10.1182/bloodadvances.2026019841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。